Navigation Links
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
Date:6/11/2008

omplishment and the inhalation-based delivery of siRNA to the respiratory system demonstrate the unique strengths of our siRNA program."

For more information on the conference please visit: http://www.beyondgenome.com/

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA locally and systemically to organs including the eye, ear, kidney, lung, spinal cord and bone marrow.

Quark's lead product, PF-4523655 (RTP801i-14), completing Phase I/IIa clinical trials, is a synthetic, chemically modified, siRNA molecule to temporarily inhibit the expression of Quark's proprietary target gene RTP801. PF-4523655 is licensed to Pfizer on an exclusive worldwide basis. Quark expects its partner, Pfizer, to continue to progress PF-4523655 through Phase II clinical trials for the treatment of AMD and diabetic macular edema (DME). In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery. Based on publicly available information, Quark believes this was the first siRNA delivered systemically in a human clinical trial. The Company has licenses for AtuRNAi(TM) technology from Silence Therapeutics and additional RNAi intellectual property from Alnylam

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 GliaCure, a privately-held ... therapies for neurological and neuropsychiatric disorders based on ... of Alzheimer,s patients in a Phase 1b clinical ... compound developed as a potential disease-modifying treatment. GliaCure,s ... in that it both promotes the clearance of ...
(Date:5/4/2015)... 4, 2015 /PRNewswire/ - The Fight Against Cancer ... to announce the formation of Turnstone Biologics Inc. ... for cancer that harness the patient,s own immune ... collaboration between the Children,s Hospital of ... University, the Ontario Institute for Cancer Research (OICR), ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... 4, 2015   Intrexon Corporation (NYSE: ... 2015 financial results after the market closes on May ... that day at 5:30 PM ET to discuss the ... The conference call may be accessed by dialing 1-888-346-3959 ... the "Intrexon Conference Call."  Participants may also access the ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2
... NV,(Euronext Brussels: THR), a biotechnology company focused on ... it has completed,patient enrolment for its Phase II ... is to evaluate the safety and preliminary efficacy ... four and twelve hours after the onset of ...
... 8, 2008 Dendreon Corporation,(Nasdaq: DNDN ) ... registered direct offering of 8.0 million shares of ... 8.0 million shares of its common,stock. Net proceeds ... Markets LLC served as sole placement agent for ...
... Ganeden Biotech,announced that Sustenex(TM), its all-natural daily ... capsule contains at least 2,billion live probiotic ... Bacillus coagulans designed to help promote immune ... designed to survive and,thrive in the digestive ...
Cached Biology Technology:ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3Dendreon Announces Closing of Registered Direct Offering 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 3
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... A new study presages a real aim of genetics: to ... of individual genetic variants for individual health. The research team, ... six novel genetic variants that are associated with lipid levels, ... power of ,genetic microscopes, has increased because the methods are ...
... Mass. Dec. 3, 2008 Interleukin-12 is a ... the human immune system. Having either too much or ... development of many diseases, including some cancers and auto-immune ... modulating interleukin-12 levels could yield new therapies for those ...
... Babraham Institute near Cambridge, supported by the Alzheimer,s ... Research Council (BBSRC), have discovered that the brain,s ... of ageing such as Alzheimer,s disease. The findings ... . Alzheimer,s disease causes nerve cells in ...
Cached Biology News:The genetic heart of the lipids 2The genetic heart of the lipids 3Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 2Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 3Maintaining the brain's wiring in aging and disease 2
Mouse monoclonal antibody to FMN2 - formin 2...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Determin interaction of your protein with Echelons lipids...
Biology Products: